Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Inclusion Criteria: * Patient is 18 years of age or older. * Patient has signed Informed Consent Form and is willing and able to abide by the protocol. * Patients diagnosed with Low Grade (LG) or High grade (HG) NMIBC. * No active urinary tract infection as confirmed by urine culture. * If the patient is a female of childbearing potential, she is using two acceptable \& effective methods of contraception, until 6 months post treatment * A negative serum pregnancy test at screening for female patient with childbearing potential * If the patient is a male he should use a condom during intercourse, for at least 48 hours post each instillation. * If the patient is a male that has a partner that is a female of childbearing potential, he should be advised to use two acceptable \& effective methods of contraception until 6 months post treatment. Exclusion Criteria: * Tumor located in prostatic urethra (for male patient) or in the bladder diverticulum. * Prior or required pelvic radiotherapy. * Systemic chemotherapy within 1 year prior the screening. * Pregnant or breastfeeding female patient. * Treatment of bladder cancer with BCG within the last 12 months prior to screening visit . Exception: For patient that had BCG treatment within 6-12 months prior to screening visit and are not symptomatic, the patient may enroll at the investigator discretion. * Treatment (full course) with intravesical chemotherapy within the 3 months, prior to screening visit. * Contraindication to MMC treatment as per investigator determination, or known sensitivity to MMC or TC-3 ingredients. * The patient has a known current urinary retention which requires intermittent catheterization to empty the bladder. * The patient has a bleeding disorder or a screening platelet count \<100X109/L. * The patient has screening hemoglobin \<10g/dL OR white blood cells \< 4000 mm3. * GFR\<30 * Hepatic values exceeding 2 times the upper normal limit. * The patient has a concurrent severe and/or uncontrolled medical condition (e.g., uncontrolled diabetes, compensated congestive heart failure \[NYHA III and over\], myocardial infarction within 6 months of screening visit, unstable or uncontrolled hypertension or an active uncontrolled infection) or psychiatric disease, which could compromise participation, compliance with scheduled visits, and/or completion of the study in the opinion of the investigator. * The patient has a documented severe vesico-ureteral reflux or has an in-dwelling ureteral stent. * The patient participated in an investigational interventional study within the past 90 days, prior to screening visit.